aTYR PHARMA (ATYR) Prepaid Assets (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Prepaid Assets came in at $518000.0 in Q2 2026, down 92.21% on a YoY basis from $6.6 million in Q2 2025, and down 11.6% quarter-over-quarter from $586000.0 in Q1 2026.
Analysis
aTYR PHARMA (ATYR) Prepaid Assets (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported Prepaid Assets for 13 consecutive years, with $518000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets fell 92.21% year-over-year to $518000.0; the trailing twelve-month figure through Jun 2026 stood at $518000.0 (down 92.21% YoY), and the FY2025 full-year result was $677000.0, down 91.63% from the prior year.
- Prepaid Assets retreated to $518000.0 in Q2 2026 per ATYR's latest filing, from $586000.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $10.2 million in Q2 2024 and bottomed at $518000.0 in Q2 2026.
- Historically, Prepaid Assets has averaged $4.7 million across 5 years, with a median of $4.2 million in 2022.
- The sharpest annual moves came in 2024 and 2026: Prepaid Assets soared 238.62% in 2024, then plunged 92.21% in 2026.
- Over 5 years, Prepaid Assets stood at $2.9 million in 2022, then slipped by 18.98% to $2.4 million in 2023, then jumped by 238.62% to $8.1 million in 2024, then plunged by 91.63% to $677000.0 in 2025, then dropped by 23.49% to $518000.0 in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $518000.0, $586000.0, and $677000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 518,000.00 |
| Mar 31, 2026 | 586,000.00 |
| Dec 31, 2025 | 677,000.00 |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 6.65 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | 8.09 Mn |
| Sep 30, 2024 | 8.50 Mn |
| Jun 30, 2024 | 10.19 Mn |
| Mar 31, 2024 | 9.94 Mn |
| Dec 31, 2023 | 2.39 Mn |
| Sep 30, 2023 | 3.08 Mn |
| Jun 30, 2023 | 4.56 Mn |
| Mar 31, 2023 | 3.44 Mn |
| Dec 31, 2022 | 2.95 Mn |
| Sep 30, 2022 | 6.39 Mn |
| Jun 30, 2022 | 4.38 Mn |
| Mar 31, 2022 | 4.03 Mn |
| Dec 31, 2021 | 5.22 Mn |
| Sep 30, 2021 | 5.09 Mn |